Journals / Journal of Experimental and Clinical Medicine / 2021 / Cilt: 38 - Sayı: 4

Comparing rLH with hMG in embryo transfers at the stage of blastocyst and pregnancy outcomes in poor responders

Pages
474–477
Publication Date
2021-10-09
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Interventions for poor responders obviously need large randomized studies which were designed properly, due to the lack of evidence-based treatment to date for this particular patient group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Objective: Despite showing the beneficial effects of adding LH activity to FSH, based on the pregnancy rate (PR) in patients in the previous studies, no studies have been done to compare two different gonadotrophin preparations with activity of LH in the same group of poor responders.
📊
Key Findings & Data:Metods: The present study was a single-center retrospective one conducted in January 2015 - December 2019 among 30 women under 39 years old who had reduced ovarian reserve and underwent ICSI cycles.
💡
Conclusion & Impact:Interventions for poor responders obviously need large randomized studies which were designed properly, due to the lack of evidence-based treatment to date for this particular patient group.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:rLH · hMG · poor responeder

Abstract

Abstract Objective: Despite showing the beneficial effects of adding LH activity to FSH, based on the pregnancy rate (PR) in patients in the previous studies, no studies have been done to compare two different gonadotrophin preparations with activity of LH in the same group of poor responders. Metods: The present study was a single-center retrospective one conducted in January 2015 - December 2019 among 30 women under 39 years old who had reduced ovarian reserve and underwent ICSI cycles. The same patient group received rFSH combined with hMG or rLH. The ovarian stimulation cycle began on the second day of the menstrual cycle, and the initial doses of gonadotrophin were 225 IU/day rFSH in addition to 75 IU/day hMG or 75 IU/day rLH. In all cycles , a flexible antagonist protocol was used. Results: Adding rLH significantly increased the mean number of MII oocytes and COC(cumulus oophorus complex) (p < 0.001). There was no significant difference between poor responders treated with rLH or with hMG in terms of blastocyst transfer,implantation rates and clinical pregnancy rates(p>0.05). Conclusion: There should be further studies to confirm the better effect of rLH addition to rFSH than hMG in young poor responders. Interventions for poor responders obviously need large randomized studies which were designed properly, due to the lack of evidence-based treatment to date for this particular patient group.

🔖

Cite This Article

GÜNGÖR, N. D., YURCİ, A., GÜRBÜZ, T., GÜNGÖR, K. (2021). Comparing rLH with hMG in embryo transfers at the stage of blastocyst and pregnancy outcomes in poor responders. Journal of Experimental and Clinical Medicine, Cilt: 38 - Sayı: 4, 474–477. https://ajindex.com/articles/677835

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Blumenfeld Z. What is the best regimen for ovarian stimulation of poor responders in ART/IVF.Front Endocrinol(Lausanne)2020.11:192. Bosch E, Labarta E, Crespo J, Simon C,Remohi J,Pellicer A.Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2011.1;95(3):1031-6.
  2. Buhler KF, Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study. Gynecol Endocrinol. 2012.28(5):345-50.
  3. Casarini L, Santi D, Brigante G, Simoni M. Two Hormones for One Receptor: Evolution, Biochemistry, Actions, and Pathophysiology of LH and hCG. Endocr Rev. 2018.1;39(5):549-92.
  4. Dahan MH, Agdi M, Shehata F, Son W,Tan S. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis. Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:70-3.
  5. Drakopoulos P, Vuong TNL, Ho NAV, Vaiarelli A,Ho MT,Blockeel C,et al. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Hum Reprod. 2017.1;32(11):2225-33.
  6. Ferraretti AP, La Marca A, Fauser BC,Tarlatzis B,Nargund G.Gianoroli L. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011.26(7):1616-24.
  7. Ferraretti AP, Gianaroli L, Motrenko T, Feliciani E,Tabanelli C,Magli MC. LH pretreatment as a novel strategy for poor responders. Biomed Res Int. 2014;2014:926172. Hill MJ, Levens ED, Levy G,Ryan M,Csokmay JM,DeCherney AH,Whitcomb BW.The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril. 2012 May;97(5):1108-14.
  8. Humaidan P, Chin W, Rogoff D,Hoohhe TD,Longobardi S,Hubbard J et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017.1;32(3):544-55.
  9. Kolibianakis EM, Venetis CA, Diedrich K,Tarlatzis BC,Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated